Medications for Tardive Dyskinesia
Tardive dyskinesia are involuntary movements, especially of the lower face, that develop after exposure to a group of medications known as neuroleptics. The abnormal movements include tongue thrusting, repetitive chewing, jaw swinging and/or facial grimacing.
The most commonly used offending neuroleptics are typical (old generation) antipsychotic medications, such as haloperidol, trifluoperazine, or fluphenazine. They act by blocking dopamine receptors in the brain.
The condition may be reversible, if recognized in the earliest stages, by stopping the causative agent, but may be permanent. On occasion, if the anti-psychotics are stopped after the tardive dyskinesia has been present for a long period, the condition may become significantly worse.
Drugs used to treat Tardive Dyskinesia
The following list of medications are in some way related to or used in the treatment of this condition.
Frequently asked questions
- What drugs cause tardive dyskinesia?
- Why should you not discontinue amantadine?
- How much does it cost?
- Austedo vs Ingrezza: How do they compare?
- What's the difference between deutetrabenazine and tetrabenazine?
- Which pharmacies can dispense Ingrezza?
- What symptoms does amantadine treat?
- Does Ingrezza cause weight gain?
- How long does it take for Ingrezza to work?
Learn more about Tardive Dyskinesia
Medicine.com guides (external)
|Rating||For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
|Activity||Activity is based on recent site visitor activity relative to other medications in the list.|
|Rx/OTC||Prescription or Over-the-counter.|
|Off-label||This medication may not be approved by the FDA for the treatment of this condition.|
|EUA||An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.|
|Expanded Access||Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.|
|A||Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).|
|B||Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.|
|C||Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.|
|D||There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.|
|X||Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.|
|N||FDA has not classified the drug.|
|Controlled Substances Act (CSA) Schedule|
|M||The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.|
|U||CSA Schedule is unknown.|
|N||Is not subject to the Controlled Substances Act.|
|1||Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.|
|2||Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.|
|3||Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.|
|4||Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.|
|5||Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.|
|X||Interacts with Alcohol.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.